This clinical trial is focused on studying a lung infection caused by a type of bacteria called Mycobacterium xenopi. The study is testing a treatment that includes a medication called ARIKAYCE, which is an inhaled form of the antibiotic amikacin. This medication is being added to the standard treatment to see if it improves the rate at which the bacteria are cleared from the lungs over a period of three months. The standard treatment may include other antibiotics such as rifampicin, amoxicillin, and ethambutol hydrochloride, which are taken orally.

The purpose of the study is to determine if adding ARIKAYCE to the usual treatment is more effective than the standard treatment alone. Participants in the study will receive either the standard treatment or the standard treatment plus ARIKAYCE. The study will monitor the participants over a period of up to six months to assess the effectiveness of the treatment in clearing the infection from the lungs. The study will also look at other outcomes such as the recurrence of the infection, any failures or relapses, and the overall safety of the treatment.

Participants will be required to undergo regular check-ups and provide samples to measure the presence of the bacteria in their lungs. The study aims to provide valuable information on the best way to treat Mycobacterium xenopi lung infections and improve patient outcomes. The results of this study could lead to better treatment options for those affected by this type of lung infection.